

Chu et. al

US PN 6,720,346


4/13/04

=> s e331
L11

1 486413-88-1/BI
(486413-88-1/RN)

=> d scan

L11 1 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-N-[2-(1-methylethoxy)ethyl]- (9CI)
MF C22 H22 F2 N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:182368 CAPLUS

DOCUMENT NUMBER: 140:229401

TITLE: Three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands

INVENTOR(S): Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004043388	A1	20040304	US 2002-234985	20020903
US 2003165873	A1	20030904	US 2002-91177	20020304
PRIORITY APPLN. INFO.:				
			US 2001-272932P	P 20010302
			US 2001-278233P	P 20010323
			US 2001-329437P	P 20011015
			US 2002-91177	A2 20020304

AB The invention provides compns. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Preparation of compds., e.g a methotrexate moiety linked by a polyethylene glycol moiety to dexamethasone, is described.


IT 223784-75-6D, conjugates

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

RN 223784-75-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-(9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:297411 CAPLUS

DOCUMENT NUMBER: 130:325142

TITLE: Preparation of 4-aminothiazole derivatives as inhibitors of cyclin-dependent kinases


INVENTOR(S): Chong, Wesley K. M.; Chu, Shao Song; Duvadie, Rohit R.; Li, Lin; Xiao, Wei; Yang, Yi

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 172 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921845	A2	19990506	WO 1998-US22809	19981027
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2306082	AA	19990506	CA 1998-2306082	19981027
AU 9913664	A1	19990517	AU 1999-13664	19981027
AU 738792	B2	20010927		
TR 200001081	T2	20001023	TR 2000-200001081	19981027
EP 1056732	A2	20001206	EP 1998-957393	19981027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
SI 20324	C	20010228	SI 1998-20068	19981027
EE 200000289	A	20010615	EE 2000-200000289	19981027
BR 9815200	A	20011016	BR 1998-15200	19981027
EP 1215208	A2	20020619	EP 2002-1881	19981027
EP 1215208	A3	20020904		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NZ 503788	A	20021126	NZ 1998-503788	19981027
US 6569878	B1	20030527	US 1998-179744	19981027
NZ 517419	A	20030829	NZ 1998-517419	19981027
JP 2004500304	T2	20040108	JP 2000-517957	19981027
NO 2000001955	A	20000616	NO 2000-1955	20000414
LT 4855	B	20011126	LT 2000-33	20000414
HR 2000000222	A1	20010228	HR 2000-222	20000417
MX 200003812	A	20001113	MX 2000-3812	20000418
LV 12592	B	20010720	LV 2000-51	20000503
BG 104478	A	20010228	BG 2000-104478	20000526
BG 64195	B1	20040430		
US 2003220326	A1	20031127	US 2003-388851	20030313
PRIORITY APPLN. INFO.:				
			US 1997-63634P	P 19971027
			US 1997-63666P	P 19971028
			EP 1998-957393	A3 19981027
			NZ 1998-503788	A1 19981027
			US 1998-179744	A3 19981027
			WO 1998-US22809	W 19981027

OTHER SOURCE(S): MARPAT 130:325142
 GI



AB Title compds. [I; wherein R1 is a (un)substituted group selected from:

alkyl, alkenyl, alkoxyl, alc., carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl, etc.; R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R independently is a halogen, haloalkyl, C-alkyl, C-alkenyl, C-alkynyl, hydroxyl, C-alkoxyl, amino, nitro, thiol, thioether, imine, cyano, amido, phosphonato, phosphine, carboxyl, thiocarbonyl, sulfonyl, sulfonamide, ketone, aldehyde, ester, oxygen, carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl], a pharmaceutically acceptable salt, a prodrug, pharmaceutically active metabolite of title compound, or pharmaceutically acceptable salt thereof, are prepared as inhibitors of cyclin-dependent kinases (CDKs: CDK1, CDK2, CDK4, and CDK6) to the therapeutic or prophylactic use of pharmaceutical compns. containing such compds. and to methods of treating malignancies and other disorders by administering effective amts. of such compds. Thus, I (R1 = C6H5; R2 = 3-NO2C6H4) was prepared with 52% yield from cyanamide, isothiocyanate, and 2-bromo-3'-nitroacetophenone in the presence of sodium.


IT 223784-25-6P 223784-75-6P 223784-98-3P
223784-99-4P 223785-00-0P 223785-07-7P
223785-50-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of 4-aminothiazoles as inhibitors of cyclin-dependent kinases)


RN 223784-25-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-amino-5-[2,6-dichloro-4-(trifluoromethyl)benzoyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)




RN 223784-75-6 CAPLUS


CN Benzenesulfonamide, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)




RN 223784-98-3 CAPLUS
 CN Benzenesulfonamide, 4-[[4-amino-5-(2,4,6-trichlorobenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)




RN 223784-99-4 CAPLUS
 CN Benzenesulfonamide, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 223785-00-0 CAPLUS
 CN Benzenesulfonamide, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 223785-07-7 CAPLUS
 CN Benzenesulfonamide, 4-[[4-amino-5-(2,4,6-trifluorobenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



RN 223785-50-0 CAPLUS
 CN Benzenesulfonamide, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



IT 223786-37-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Preparation of 4-aminothiazoles as inhibitors of cyclin-dependent kinases)

RN 223786-37-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]phenyl]sulfonyl]amino]methyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)

